Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the DRC
NCT02977715Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Feb 2017
- Primary completion
- Oct 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label trial of JYNNEOS in mpox (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Monkeypox virus infection at 2 years, Monkeypox virus exposure at 2 years and 3 more. Started Feb 2017; status: completed.
02
Drugs
JYNNEOS
03
Conditions
mpox
Beyond the preview
Go deeper on NCT02977715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977715.